Abstract:Abstract Introduction The prognosis for patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) is very poor under current therapeutic modalities. Recently chimeric antigen receptor modified T cells against CD19 (CART19) have shown promise as a novel therapy for R/R ALL patients in clinical trials. In our clinical trial, we found that CART19 had potent anti-leukemia activities in Chinese patients with R/R ALL (Yongxian Hu, He Huang et al; No.O168, oral presentation, EBMT 2016). In the current study we sought to determine whether CART19, results in better clinical outcomes in patients with R/R ALL than does chemotherapy (ChiCTR- ORN-16008948). Methods We compared the effectiveness and toxicities of CART19 therapy in 17 R/R ALL patients (CART19 group) against a historical control group of 42 patients who received standard or salvage chemotherapy (Chemotherapy group). For some patients who relapsed after allogeneic hematopoietic stem cell transplantation (HSCT), donor lymphocyte infusion and chemotherapy were combined. Results 7 (41.2%) and 15 (35.7%) patients were relapsed after allogeneic HSCT in the CART19 group and the chemotherapy group respectively. The rate of complete remission was significantly higher in the CART19 group than in the chemotherapy group (93.3% [95% confidence interval (CI), 68.1 to 99.8] vs. 40.5% [95% CI, 25.6 to 56.7], P<0.001). Among the patients who had complete remission, a higher percentage in the CART19 group had results below the threshold for minimal residual disease (0.01% marrow blasts) (100% vs 23.7%, P<0.001). 5 (29.4%) and 2 (4.8%) of patients who achieved complete remission in the 2 groups underwent subsequent haploidentical HSCT (2 for the second transplantation). In the survival analysis, the overall survival rate at 12 months was significantly higher in the CART19 group than in the chemotherapy group (65.4% vs 14.6% hazard ratio, 0.36 [95 % CI, 0.20 to 0.81]; P=0.0175) (Figure 1A). In the chemotherapy group, the causes of death included primary disease progression (24 patients), infection (10 patients) and intracranial hemorrhage (1 patient) while in the CART19 group the causes of death included primary disease progression (3 patients) and infection (3 patients). Cytokine release syndrome (CRS) was the most side effect in CART19 therapy. 12 (70.6%) of 17 patients suffered from CRS. The Grade 3 CRS developed in 6 (35.3%) of patients. The CRS syndrome was fully reversible after treatment with supportive care alone (n=6), supportive care plus the anti-interleukin-6 receptor monoclonal antibody, tocilizumab (n=3), supportive care plus tocilizumab and corticosteroids (n=2), as well as supportive care plus corticosteroids (n=1). CART19-related other adverse events were reversible neurotoxicity and pancytopenia consistent with previous reports. In the chemotherapy group, pancytopenia was the major toxicity. For patients who achieved complete remission, the median duration of absolute neutrophil count less than 500/¦ÌL was longer in the CART19 group than in the chemotherapy group [22.07±7.66 days (95% CI , 17.65 to 26.49) vs 16.06±3.66 days (95% CI , 14.17 to 17.94) , p=0.0076] (Figure 1B). Conclusions For the first time our study found thatCART19 therapy could greatly improved rates of complete remission and overall survival compared to conventional chemotherapy in R/R ALL patients. Our data suggest that CART19 turns to provide a new therapeutic approach for patients with R/R ALL. This novel targeted immune therapy provides more patients with R/R ALL opportunities for further interventional therapeutic strategies such as the secondary CART19 therapy, targeted drug therapy and haploidentical HSCT, even the second allo-HSCT, to improve the long-term overall clinical outcomes in patients with high-risk of relapse after CART19 therapy. Disclosures No relevant conflicts of interest to declare.

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients

Superior Therapeutic Efficacy of Chimeric Antigen Receptor Modified T Cells Against CD19 over Chemotherapy in Relapsed/Refractory Acute Lymphocytic Leukemia

Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma

Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: an Open-Label, Single-Arm, Phase Ⅰ/Ⅱ Trial

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia

415. First-In-Patient Proof of Safety and Efficacy of a 4th Generation Chimeric Antigen Receptor-Modified T Cells for the Treatment of Relapsed or Refractory CD30 Positive Lymphomas

Potent Anti-Leukemia Activities of Humanized CD19-targeted Chimeric Antigen Receptor T (CAR-T) Cells in Patients with Relapsed/refractory Acute Lymphoblastic Leukemia.

A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity

Supplementary Tables from Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: an Open-Label Phase I Trial

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin's Lymphoma.

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma

Potent Anti-Leukemia Activities of Chimeric Antigen Receptor-Modified T Cells Against Cd19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30 + lymphoma: a phase 1 study

Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study

Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report

Chimeric antigen receptor-modified T cells directed against CD19 in patients with relapsed or refractory CD19-positive B-cell lymphomas: interim analysis of a phase 1 study

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia